Cargando…

A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers

Background: Fibroblast growth factor receptor 2 (FGFR2) is frequently altered in tumors and one of the top therapeutic targets in cholangiocarcinoma (CHOL) with FGFR2 fusions. Although there have been several studies on individual tumors, a comprehensive analysis of FGFR2 genetic aberrations and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Juanni, Hu, Kuan, Huang, Jinzhou, Zhou, Lei, Yan, Yuanliang, Xu, Zhijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097147/
https://www.ncbi.nlm.nih.gov/pubmed/33968743
http://dx.doi.org/10.3389/fonc.2021.644854
_version_ 1783688296144044032
author Li, Juanni
Hu, Kuan
Huang, Jinzhou
Zhou, Lei
Yan, Yuanliang
Xu, Zhijie
author_facet Li, Juanni
Hu, Kuan
Huang, Jinzhou
Zhou, Lei
Yan, Yuanliang
Xu, Zhijie
author_sort Li, Juanni
collection PubMed
description Background: Fibroblast growth factor receptor 2 (FGFR2) is frequently altered in tumors and one of the top therapeutic targets in cholangiocarcinoma (CHOL) with FGFR2 fusions. Although there have been several studies on individual tumors, a comprehensive analysis of FGFR2 genetic aberrations and their simultaneous clinical implications across different tumors have not been reported. Methods: In this study, we used the large comprehensive datasets available, covering over 10,000 tumor samples across more than 30 cancer types, to analyze FGFR2 abnormal expression, methylation, alteration (mutations/fusions and amplification/deletion), and their clinical associations. Results: Alteration frequency, mutation location distribution, oncogenic effects, and therapeutic implications varied among different cancers. The overall mutation rate of FGFR2 is low in pancancer. CHOL had the highest mutation frequency, and fusion accounted for the major proportion. All these fusion aberrations in CHOL were targetable, and an FDA-approved drug was approved recently. Uterine corpus endometrial carcinoma (UCEC) had the highest number of FGFR2 mutations, and the most frequently mutated positions were S252W and N549K, where the functional impact was oncogenic, but targeted therapy was less effective. Additionally, DNA methylation was associated with FGFR2 expression in several cancers. Moreover, FGFG2 expression and genetic aberrations showed clinical associations with patient survival in several cancers, indicating their potential for application as new tumor markers and therapeutic targets. Conclusions: This study showed the full FGFR2 alteration spectrum and provided a broad molecular perspective of FGFR2 in a comprehensive manner, suggesting some new directions for clinical targeted therapy of cancers.
format Online
Article
Text
id pubmed-8097147
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80971472021-05-06 A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers Li, Juanni Hu, Kuan Huang, Jinzhou Zhou, Lei Yan, Yuanliang Xu, Zhijie Front Oncol Oncology Background: Fibroblast growth factor receptor 2 (FGFR2) is frequently altered in tumors and one of the top therapeutic targets in cholangiocarcinoma (CHOL) with FGFR2 fusions. Although there have been several studies on individual tumors, a comprehensive analysis of FGFR2 genetic aberrations and their simultaneous clinical implications across different tumors have not been reported. Methods: In this study, we used the large comprehensive datasets available, covering over 10,000 tumor samples across more than 30 cancer types, to analyze FGFR2 abnormal expression, methylation, alteration (mutations/fusions and amplification/deletion), and their clinical associations. Results: Alteration frequency, mutation location distribution, oncogenic effects, and therapeutic implications varied among different cancers. The overall mutation rate of FGFR2 is low in pancancer. CHOL had the highest mutation frequency, and fusion accounted for the major proportion. All these fusion aberrations in CHOL were targetable, and an FDA-approved drug was approved recently. Uterine corpus endometrial carcinoma (UCEC) had the highest number of FGFR2 mutations, and the most frequently mutated positions were S252W and N549K, where the functional impact was oncogenic, but targeted therapy was less effective. Additionally, DNA methylation was associated with FGFR2 expression in several cancers. Moreover, FGFG2 expression and genetic aberrations showed clinical associations with patient survival in several cancers, indicating their potential for application as new tumor markers and therapeutic targets. Conclusions: This study showed the full FGFR2 alteration spectrum and provided a broad molecular perspective of FGFR2 in a comprehensive manner, suggesting some new directions for clinical targeted therapy of cancers. Frontiers Media S.A. 2021-04-21 /pmc/articles/PMC8097147/ /pubmed/33968743 http://dx.doi.org/10.3389/fonc.2021.644854 Text en Copyright © 2021 Li, Hu, Huang, Zhou, Yan and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Juanni
Hu, Kuan
Huang, Jinzhou
Zhou, Lei
Yan, Yuanliang
Xu, Zhijie
A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers
title A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers
title_full A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers
title_fullStr A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers
title_full_unstemmed A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers
title_short A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers
title_sort pancancer analysis of the expression landscape and clinical relevance of fibroblast growth factor receptor 2 in human cancers
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097147/
https://www.ncbi.nlm.nih.gov/pubmed/33968743
http://dx.doi.org/10.3389/fonc.2021.644854
work_keys_str_mv AT lijuanni apancanceranalysisoftheexpressionlandscapeandclinicalrelevanceoffibroblastgrowthfactorreceptor2inhumancancers
AT hukuan apancanceranalysisoftheexpressionlandscapeandclinicalrelevanceoffibroblastgrowthfactorreceptor2inhumancancers
AT huangjinzhou apancanceranalysisoftheexpressionlandscapeandclinicalrelevanceoffibroblastgrowthfactorreceptor2inhumancancers
AT zhoulei apancanceranalysisoftheexpressionlandscapeandclinicalrelevanceoffibroblastgrowthfactorreceptor2inhumancancers
AT yanyuanliang apancanceranalysisoftheexpressionlandscapeandclinicalrelevanceoffibroblastgrowthfactorreceptor2inhumancancers
AT xuzhijie apancanceranalysisoftheexpressionlandscapeandclinicalrelevanceoffibroblastgrowthfactorreceptor2inhumancancers
AT lijuanni pancanceranalysisoftheexpressionlandscapeandclinicalrelevanceoffibroblastgrowthfactorreceptor2inhumancancers
AT hukuan pancanceranalysisoftheexpressionlandscapeandclinicalrelevanceoffibroblastgrowthfactorreceptor2inhumancancers
AT huangjinzhou pancanceranalysisoftheexpressionlandscapeandclinicalrelevanceoffibroblastgrowthfactorreceptor2inhumancancers
AT zhoulei pancanceranalysisoftheexpressionlandscapeandclinicalrelevanceoffibroblastgrowthfactorreceptor2inhumancancers
AT yanyuanliang pancanceranalysisoftheexpressionlandscapeandclinicalrelevanceoffibroblastgrowthfactorreceptor2inhumancancers
AT xuzhijie pancanceranalysisoftheexpressionlandscapeandclinicalrelevanceoffibroblastgrowthfactorreceptor2inhumancancers